Latest Breaking News On - Deena beasley - Page 19 : comparemela.com

Amgen quarterly revenue rises 6%, profit beats Street estimates

(Reuters) -Amgen, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics, on Thursday reported higher quarterly profit on strong sales of treatments for cholesterol, osteoporosis and other drugs. The biotech company, which slightly raised its outlook for full-year revenue and profit, said it currently expects the Horizon deal to close by mid-December. For the second quarter, Amgen reported revenue of $6.99 billion, up 6% from a year earlier, exceeding analysts' estimates of $6.68 billion, according to Refinitiv data.

United statesPeter griffithDeena beasleyUs federal trade commissionTrade commissionHorizon therapeuticsChief financial officer peter griffithWall streetBill berkrot

Amgen quarterly revenue rises 6%, profit beats Street estimates

(Reuters) -Amgen, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics, on Thursday reported higher quarterly profit on strong sales of treatments for cholesterol, osteoporosis and other drugs. The biotech company, which slightly raised its outlook for full-year revenue and profit, said it currently expects the Horizon deal to close by mid-December. For the second quarter, Amgen reported revenue of $6.99 billion, up 6% from a year earlier, exceeding analysts' estimates of $6.68 billion, according to Refinitiv data.

United statesDeena beasleyPeter griffithUs federal trade commissionTrade commissionHorizon therapeuticsChief financial officer peter griffithWall streetBill berkrot

Gilead quarterly profit falls on COVID sales drop, legal settlement charge

(Reuters) -Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs. The drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations. Gilead reported second-quarter earnings of $1.34 per share excluding items, on total revenue of $6.6 billion, down from $1.58 a share and revenue of $6.26 billion in the year-ago quarter.

United statesDeena beasleyGilead sciences onWall streetReporting by deena beasleyMichael ermanBill berkrot

Experimental drug works best for Alzheimer s patients treated as early as possible

Experimental drug works best for Alzheimer s patients treated as early as possible
gazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazette.com Daily Mail and Mail on Sunday newspapers.

Noord hollandUnited statesLudwig burgerSusan kohlhaasEli lillyAnne whiteDeena beasleyLiz coulthardReisa sperlingJulie steenhuyseneditingCaroline humerIndiana university school of medicineUniversity of bristolYork stock exchangeUn world health organizationAlzheimer research united kingdom

Lilly Drug Slows Alzheimer s By 60% For Mildly Impaired Patients In Trial

Lilly Drug Slows Alzheimer s By 60% For Mildly Impaired Patients In Trial
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Noord hollandUnited statesDeena beasleyEli lillyAnne whiteCaroline humerLiz coulthardUniversity of bristolDrug administrationYork stock exchangeAlzheimer association international conferenceNew york stock exchangeIndiana university school of medicineAlzheimer associationLiana apostolovaIndiana university school